DeNovaMed https://validator.w3.org/feed/docs/rss2.html Home Therapeutic Areas DeNovaMed DNM0547 Program Published in Nature Communications About Us Christopher Barden, PhD Media release: Dalhousie University researchers, DeNovaMed Inc. develop new family of antibiotics that could treat multidrug‑resistant bacterial ‘superbugs’ DeNovaMed DNM0547 DeNovoMed DNM0904 Technology News & Publications Contact Us Additional Q4 2024 Press Coverage of DeNovaMed Antibiotic Programs Donald Weaver, MD, PhD Christopher McMaster, PhD Marlene Haffner, MD, MPH David Armstrong, MD, PhD Z. Sam Ruttonsha, B.Sc, MBA Diabetic Foot Ulcers Cellulitis MRSA Infections Drug-Resistant Bacterial Infections Peripheral Arterial Disease Infections Anthrax Gram-Positive and Negative Infections Leprosy